AIP
TEVA icon

Arrowpoint Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Arrowpoint Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Buy
81,993
+56,188
+218% +$1.87M 0.61% 35
2026
Q1 		$777K Sell
25,805
-126,907
-83% -$4.08M 0.69% 29
2025
Q4 		$4.77M Buy
+152,712
New +$3.76M 0.7% 17

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Arrowpoint Investment Partners's TEVA Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its Teva Pharmaceuticals (TEVA) stake by 218% in Q2 2026, buying an estimated $1.87M and bringing the position to 81,993 shares worth $2.78M. The position accounts for 0.61% of the portfolio, ranked #35.

Arrowpoint Investment Partners first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.77M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Arrowpoint Investment Partners held 81,993 shares of Teva Pharmaceuticals worth $2.78M as of Q2 2026.
  • Arrowpoint Investment Partners bought 56,188 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.87M.
  • Teva Pharmaceuticals made up 0.61% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #35 holding.
  • Arrowpoint Investment Partners first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Arrowpoint Investment Partners's Teva Pharmaceuticals position peaked at $4.77M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.